Hydroxychloroquine: balancing the needs of LMICs during the COVID-19 pandemic.
MetadataShow full item record
Banerjee, S. (2020). Hydroxychloroquine: balancing the needs of LMICs during the COVID-19 pandemic.. Lancet Rheumatology, 2 (7), e385-e386. https://doi.org/10.1016/S2665-9913(20)30162-4
I want to thank the Editor for bringing attention to the effect of a potential shortage of hydroxychloroquine (HCQ) on existing patients with autoimmune diseases during the current COVID-19 crisis . The drug has shown some promising results against SARS-CoV-2, although more testing needs to be done. However, hydroxychloroquine is also an effective medication for patients with autoimmune disorders like systemic lupus erythematosus .
Embargo Lift Date
External DOI: https://doi.org/10.1016/S2665-9913(20)30162-4
This record's URL: https://www.repository.cam.ac.uk/handle/1810/310375
All rights reserved